晚期非小细胞肺癌患者血液EGFR突变的大规模前瞻性筛查以指导治疗决策
该前瞻性研究在119家医院纳入1138例无组织或组织不足的晚期非小细胞肺癌患者,用实时PCR检测血清和血浆游离DNA的EGFR突变。初诊患者可评估1026例,cfDNA检出致敏突变113例(11%);仅基于血液EGFR阳性一线TKI治疗的患者ORR为72%,中位PFS为11个月。结论认为大规模血液EGFR检测可行,可在无法组织检测时用于选择靶向治疗。
要点
- 初诊晚期NSCLC患者cfDNA致敏突变检出率为11%(113/1026)。
- 仅基于血液EGFR阳性一线TKI治疗的患者ORR为72%,中位PFS为11个月。
- TKI进展后筛查者致敏突变56.2%,p.T790M耐药突变35.2%。
核心结论
- 在未经选择的晚期NSCLC患者中进行大规模血液EGFR检测是可行的,当无法进行组织检测时可用于选择靶向治疗。
- 所识别出的EGFR突变患者的特征及其对TKI治疗的临床结局与肿瘤阳性者无法区分。
研究设计与样本
- 前瞻性研究,血液样本来自119家医院的1138例晚期NSCLC患者,其中初诊时采集1033例、TKI进展后采集105例,均无活检或肿瘤组织不足。
- 血清和血浆送至中心实验室,纯化cfDNA后用实时PCR assay分析和定量EGFR突变。
- 回顾性收集了18例患者的缓解数据。
主要发现
- 1033例初诊NSCLC患者中1026例可评估,男性及既往或当前吸烟者占多数。
- 113例(11%)cfDNA中发现致敏突变,以女性、从不吸烟者和外显子19缺失为主。
- 31例仅血浆阳性、11例仅血清阳性,血浆及外显子19缺失病例的突变负荷更高。
- 超过50%的样本突变基因组<10 pg/µl,等位基因分数低于0.25%。
- 仅基于血液EGFR阳性一线TKI治疗的患者ORR为72%,中位PFS为11个月。
关键数值与推荐
- 初诊患者cfDNA致敏突变检出率为11%(113/1026)。
- 仅基于血液EGFR阳性一线TKI治疗的患者ORR为72%,中位PFS为11个月。
- TKI进展后筛查者致敏突变56.2%,p.T790M耐药突变35.2%。
- 31例仅血浆阳性,11例仅血清阳性。
- 超过50%的样本突变基因组<10 pg/µl,等位基因分数低于0.25%。
临床怎么用
- 原文结论认为大规模血液EGFR检测可行,可在无法组织检测时用于选择靶向治疗。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a significant percentage of advanced non-small-cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively analyzed if circulating-free DNA (cfDNA) purified from blood can be used as a surrogate in this setting to select patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). PATIENTS AND METHODS: Blood samples were collected in 119 hospitals from 1138 advanced NSCLC patients at presentation (n = 1033) or at progression to EGFR-TKIs (n = 105) with no biopsy or insufficient tumor tissue. Serum and plasma were sent to a central laboratory, cfDNA purified and EGFR mutations analyzed and quantified using a real-time PCR assay. Response data from a subset of patients (n = 18) were retrospectively collected. RESULTS: Of 1033 NSCLC patients at presentation, 1026 were assessable; with a prevalence of males and former or current smokers. Sensitizing mutations were found in the cfDNA of 113 patients (11%); with a majority of females, never smokers and exon 19 deletions. Thirty-one patients were positive only in plasma and 11 in serum alone and mutation load was higher in plasma and in cases with exon 19 deletions. More than 50% of samples had <10 pg mutated genomes/µl with allelic fractions below 0.25%. Patients treated first line with TKIs based exclusively on EGFR positivity in blood had an ORR of 72% and a median PFS of 11 months. Of 105 patients screened after progression to EGFR-TKIs, sensitizing mutations were found in 56.2% and the p.T790M resistance mutation in 35.2%. CONCLUSIONS: Large-scale EGFR testing in the blood of unselected advanced NSCLC patients is feasible and can be used to select patients for targeted therapy when testing cannot be done in tissue. The characteristics and clinical outcomes to TKI treatment of the EGFR-mutated patients identified are undistinguishable from those positive in tumor.
引用
- Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, et al. Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. Ann Oncol. 2017. PMID: 28911086. doi:10.1093/annonc/mdx288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。